Wiener klinische Wochenschrift

, Volume 128, Issue 15–16, pp 586–591 | Cite as

Association of cytomegalovirus infection with hypertension risk: a meta-analysis

  • Jing Hui
  • Yuan-yuan Qu
  • Na Tang
  • Yong-min Liu
  • Hua Zhong
  • La-mei Wang
  • Qian Feng
  • Zhen Li
  • Fang HeEmail author
Open Access
case report



Information regarding association between cytomegalovirus (CMV) infection and essential hypertension (EH) risk is not consistent across studies. Therefore, we conducted a meta-analysis to investigate the association in detail.


We comprehensively searched the published literature from the PubMed and Embase databases for any study analyzing the association between CMV and EH risk. A random-effects model was used to calculate the pooled odds ratio (OR) with 95 % confidence interval (CI).


Three studies involving 9657 patients were included in the meta-analysis, and the results showed a significantly increased risk of EH in patients with CMV infection. Overall, 79.3 % of the hypertension patients were CMV-positive, which was significantly higher than the percentage for controls (OR = 1.39, 95 % CI = 0.95–2.05, P = 0.017). There was significant heterogeneity among the studies included (I2 = 70.5 %). The funnel plot and Egger’s test also indicated no publication bias.


The results showed a significant association between CMV and EH, which indicates that CMV infection is a possible cause of EH.


Cytomegalovirus Essential hypertension Meta-analysis 


Essential hypertension (EH) is the most common form of hypertension [1] and is a major risk factor for cardiovascular, cerebrovascular, and renal diseases. Hypertension is a multifactorial disease [2], and its development involves both genetic and environmental factors; however, the specific mechanism and risk factors remain unclear.

As a member of the human Herpesviridae family, cytomegalovirus (CMV) contains double-stranded DNA [3] and establishes a latent infection that can persist for the lifetime of the host. Despite being nearly ubiquitous in the population [4], overt human CMV disease in adults is typically restricted to immunocompromised individuals [5, 6, 7]. In healthy individuals, both primary infection and the reactivation of latent virus rarely cause any significant clinical symptoms owing to the robust immune response of the host.

CMV infection is associated with various chronic inflammatory diseases, including cardiovascular diseases (CVDs) [8] such as myocarditis, atherosclerosis, and coronary artery disease [9, 10, 11]. Hypertension is an important cause of CVDs, and recent studies [12, 13, 14, 15, 16, 17, 18] have shown that patients with a CMV infection have an increased risk of EH; however, the association between CMV and EH remains unclear, and thus the effect of CMV infection on blood pressure is controversial. Therefore, we performed the present meta-analysis to more comprehensively investigate the association between CMV and EH.

Materials and methods

Literature search and selection

We comprehensively searched the PubMed and Embase databases up to July 2015. The search key words used included “EH or hypertension”, “blood pressure”, and “CMV”. Relevant articles in the reference lists of the published literature were also searched manually for other potential studies.

Inclusion and exclusion criteria

Studies were included in the meta-analysis if they met the following criteria (1) case-control study, (2) investigated the positive rate of CMV in hypertension patients and controls, (3) hypertension is defined as systolic blood pressure (SBP) or diastolic blood pressure (DBP) of 140 or 90 mmHg, respectively, (4) not an animal study. Studies were excluded if insufficient details were reported to be able to perform the meta-analysis.

Data extraction

Two authors (JH and Y-YQ) extracted the data independently. In cases where any data were lacking from an article, the authors of selected studies were contacted directly for the missing data. The two reviewers came to an agreement before the final analysis. The following information was extracted from each study: first author’s name, year of publication, country, ethnicity, CMV detection method, patient characteristics, the sample sizes of cases and controls, and the relationship between CMV and EH.

Statistical analysis

We performed statistical analyses using Stata statistical software ver.12.0. (Stata Corporation, College Station, TX, USA). Meta-analysis was conducted by combining odds ratios (ORs) with corresponding 95 % confidence intervals (CIs) for the association between the CMV-positive rate of hypertension patients and controls. Heterogeneity across all selected studies was evaluated using the Q-test and the I2 statistic (range 0–100 %) [19] and was judged to be significant when P < 0.1 or I2 > 50 %, respectively. We select the random-effects model in the analysis if significant heterogeneity was observed across studies; otherwise, the fixed-effects model was used. Sensitivity analysis was performed with the random-effects model to evaluate the stability of the crude results by removing one study at a time. The Begg’s funnel plot and Egger’s linear regression test were performed to determine the level of potential publication bias [20, 21]. A P-value lower than 0.05 was considered statistically significant.


Characteristics of studies included

A total of three articles [12, 13, 16] were included in the meta-analysis, comprising 2347 cases and 7310 controls. All of the studies used enzyme-linked immunosorbent assay (ELISA), and one study [12] used a combination of ELISA and polymerase chain reaction (PCR). ELISA was used to determine the titer of anti-HCMV IgG antibodies, and quantitative PCR was used to test the HCMV DNA copy number. The flow diagram for the search process is shown in Fig. 1. The characteristics of the selected studies are given in Table 1.

Fig. 1

Flow diagram of the study selection process

Table 1

Details of studies included in the meta-analysis




CMV detection


Male (%)

Cases (n = 2347)

Controls (n = 7310)


















CMV antibody titers associated with blood pressure and hypertension








CMV seropositivity associated with hypertension in males











Pathogen burden not associated with hypertension











CMV seropositivity associated with hypertension in women

ELSA enzyme-linked immunosorbent assay, PCR polymerase chain reaction, CMV cytomegalovirus

Meta-analysis results

We pooled data from all studies included and analyzed the association between CMV and EH risk. A total of 79.3 % of the hypertension patients were CMV-positive compared with 64.2 % of the controls. The pooled OR was 1.39 (95 % CI = 0.95–2.05, P = 0.017). We used a random-effects model, given the significant heterogeneity (I2 = 70.5 %) observed across studies. The overall result of the meta-analysis is shown as a forest plot in Fig. 2.

Fig. 2

Forest plot of the cytomegalovirus (CMV)-positive rate in hypertension patients versus controls. OR odds ratio, CI confidence interval

Sensitivity analysis

Sensitivity analysis was conducted to evaluate the stability of the crude results. The results showed that no single study substantially affected the stability of the crude results, given the lack of change in the ORs after exclusion of one study at a time (Fig. 3). Therefore, the results of this meta-analysis were deemed to be reliable.

Fig. 3

Sensitivity analysis

Publication bias

Begg’s funnel plot and Egger’s test were used to evaluate the potential publication bias. Although Begg’s funnel plot was not symmetrical, the Egger’s linear regression test indicated that there was no significant publication bias (Fig. 4; P = 0.361).

Fig. 4

Funnel plot to evaluate potential publication bias in studies evaluating the association between cytomegalovirus (CMV) and essential hypertension risk


CMV infection has been reported to be associated with hypertension [12, 13, 14, 15, 16, 17, 18]. Regardless of the approach used, both negative and positive associations have been reported; therefore, the role of CMV in hypertension remains controversial. Discrepancies between different studies might be due to differences in sample size, age, ethnicity, region, dietary habits, climate, lifestyles, and immune responses to CMV infection, among other factors. Besides, the seroprevalence is considerably high in China [12] to other evaluated studies’ countries, we believe that low socioeconomic status is also a factor affecting the seropositivity [22] in most Asian countries that are still developing countries, especially China.

When a human is first infected, CMV replicates in many different cells. The virus can remain a latent state for the life of its host. In most immunocompetent individuals, the CMV infection is mild or even asymptomatic. Viruses modulate the intracellular environment so that it is optimized to support the viral life cycle. With heightened stress or immunosuppression, however, latent CMV can be reactivated reinitiating productive replication and causing clinical problems, especially in immunosuppressed or immunocompromised patients. Moreover, CMV infection has been shown to be associated with the increased arterial blood pressure via stimulation with renin and cytokine production in mice [23].

Recently, several previous studies have investigated the role of CMV seropositivity as a risk factor for hypertension. In a Chinese cohort, Tang et al. [12]. showed that CMV seropositivity was significantly associated with hypertension after adjustment for age in Kazakh males but not in females. However, in another study cohort [13], CMV seropositivity was associated with hypertension in females before, but not after, adjusting for age. By contrast, another study in a Chinese cohort [14] showed that plasma CMV deoxyribonucleic acid (DNA) copy number was associated with hypertension.

Few studies have examined the CMV antibody titer as a risk factor for hypertension. One study [15] showed that CMV antibody titers were independent determinants for SBP and DBP elevation in young males but not in females. By contrast, Tang et al. [12] demonstrated that, in both Han Chinese males and females, CMV antibody titers were significantly independently associated with hypertension. However, Vahdat et al. [16] failed to show any significant association between viral infections and hypertension in patients from Iran.

In this meta-analysis, we selected three studies [12, 13, 16], including 2347 cases and 7310 controls; all the studies included were population-based cross-sectional studies. We constructed a forest plot to obtain the pooled OR and demonstrated that patients with CMV infection showed a higher risk of EH. Although the mechanism underlying how CMV might cause EH remains unclear, there are several possible explanations for this link. First, oxidative stress and inflammation might play a role [24, 25]. Reactive oxygen species (ROS) have been shown to be generated in response to CMV infection [26] and are also directly involved in vasoconstriction [27, 28, 29, 30] and vascular inflammation [31]. CMV infection can induce an inflammatory reaction through modulation of inflammatory mediators that evoke vasoconstriction, such as cytokines, chemokines, and adhesion molecules [32, 33, 34]. Second, CMV might influence hypertension via regulation of the renin-angiotensin system. CMV infection has been shown to induce the generation of angiotensin II (AngII) [25], which reacts with endothelial nitric oxide synthase to promote vasoconstriction; this may also enhance the production of ROS [35, 36]. An in vivo experimental study showed that CMV infection increased arterial pressure and further stimulated the expression of renin and increased AngII levels in the blood and arterial tissues [23], which can lead to arterial constriction. Third, the immune response triggered by CMV infection could itself lead to hypertension. Indeed, suppression of the immune system has been shown to depress blood pressure in both experimental animals and humans [37]. Finally, genomic-related changes could be involved in the mechanism. In particular, DNA methylation of gene promoter region [38, 39, 40] and the corresponding changes in mRNA expression [14] are also involved in regulating blood pressure. The studies included there are not enough, so we need more prospective studies to prove the link.

The results of the present meta-analysis suggest that CMV may be a contributing factor to the development of EH. However, there are limitations to the meta-analysis that should be acknowledged. First, although the pooled sample size of the studies included was sufficiently large to carry out the meta-analysis, the number of studies included is not as large as we had hoped for in order to perform a comprehensive analysis. In particular, this limited our ability to conduct a subgroup analysis to explore the influence of sample size, ethnicity, age, or other factors and to explore the nature of the observed heterogeneity. Therefore, these findings should be interpreted with caution, and more studies are needed to confirm the results of this meta-analysis.


The results showed a significant association between CMV and EH, which indicates that CMV infection is a possible cause of EH.

Source of support

This project was supported by the Joint Funds of the National Natural Science Foundation of China (No.U1403123) and the Ministry of Major Science & Technology of Shihezi University (Nos.gxjs2013-zdgg04, gxjs2013-zdgg04-1, gxjs2013-zdgg04-2, gxjs2013-zdgg04-3, and gxjs2013-zdgg04-4) and the Xinjiang Graduate Student Research Innovation Project (No. XJGRI2015054). No conflict of interest exists in this study.


Compliance with ethical standards

Conflicts of interest

J. Hui, Y.-y. Qu, N. Tang, Y.-m. Liu, H. Zhong, L.-m. Wang, Q. Feng, Z. Li, and F. He declare that there are no actual or potential conflicts of interest in relation to this article.


  1. 1.
    Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med. 2003;139:761–76.CrossRefPubMedGoogle Scholar
  2. 2.
    Kuneš J, Zicha J. The interaction of genetic and environmental factors in the etiology of hypertension. Physiol Res. 2009;58:S33.PubMedGoogle Scholar
  3. 3.
    Dolan A, Cunningham C, Hector RD, et al. Genetic content of wild-type human cytomegalovirus. J Gen Virol. 2004;85:1301–12.CrossRefPubMedGoogle Scholar
  4. 4.
    Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010;20:202–13.CrossRefPubMedGoogle Scholar
  5. 5.
    Drew WL. Cytomegalovirus infection in patients with AIDS. Clin Infect Dis. 1992;14:608–15.CrossRefGoogle Scholar
  6. 6.
    Griffiths PD, Clark DA, Emery VC. Betaherpesviruses in transplant recipients. J Antimicrob Chemother. 2000;45:29–34.CrossRefPubMedGoogle Scholar
  7. 7.
    Gandhi MK, Wills MR, Sissons JG, et al. Human cytomegalovirus-specific immunity following mopoietic stem cell transplantation. Blood Rev. 2003;17:259–64.CrossRefGoogle Scholar
  8. 8.
    Soderberg-Naucler C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? J Intern Med. 2006;259:219–46.CrossRefPubMedGoogle Scholar
  9. 9.
    Haider AW, Wilson PW, Larson MG, et al. The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: a prospective study. J Am Coll Cardiol. 2002;40:1408–13.CrossRefGoogle Scholar
  10. 10.
    Adler SP, Hur JK, Wang JB, et al. Prior infection with cytomegalovirus is not a major risk factor for angiographically demonstrated coronary artery atherosclerosis. J Infect Dis. 1998;177:209–12.CrossRefPubMedGoogle Scholar
  11. 11.
    Simmonds J, Fenton M, Dewar C, et al. Endothelial dysfunction and cytomegalovirus replication in pediatric heart transplantation. Circulation. 2008;117:2657–61.CrossRefPubMedGoogle Scholar
  12. 12.
    Tang N, Li JW, Liu YM, et al. Human Cytomegalovirus infection is associated with essential hypertension in Kazakh and Han Chinese populations. Med Sci Monit. 2014;20:2508–19.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Li C, Samaranayake NR, Ong KL, et al. Is human cytomegalovirus infection associated with hypertension? The United States National Health and Nutrition Examination Survey 1999–2002. PLoS One. 2012;7:e39760.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Li S, Zhu J, Zhang W, et al. Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection. Circulation. 2011;124:175–84.CrossRefGoogle Scholar
  15. 15.
    Haarala A, Kähönen M, Lehtimäki T, et al. Relation of high cytomegalovirus antibody titres to blood pressure and brachial artery flow-mediated dilation in young men: the Cardiovascular Risk in Young Finns Study. Clin Exp Immunol. 2012;167:309–16.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Vahdat K, Pourbehi MR, Ostovar A, et al. Association of pathogen burden and hypertension: the Persian Gulf Healthy Heart Study. Am J Hypertens. 2013;26:1140–47.CrossRefPubMedGoogle Scholar
  17. 17.
    Zhao P, Ma D, Xue F, et al. Seroprevalence and risk factors of human cytomegalovirus infection in the eastern Chinese population. Arch Virol. 2009;154:561–64.CrossRefPubMedGoogle Scholar
  18. 18.
    Jeong SJ, Han SH, Kim CO, et al. Association between human cytomegalovirus antibody levels, and essential hypertension and functional status in elderly Koreans. Geriatr Gerontol Int. 2014. doi: 10.1111/ggi.12428.Google Scholar
  19. 19.
    Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.CrossRefPubMedGoogle Scholar
  21. 21.
    Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010;20(4):202–13.CrossRefPubMedGoogle Scholar
  23. 23.
    Cheng J, Ke Q, Jin Z, et al. Cytomegalovirus infection causes an increase of arterial blood pressure. PLoS Pathog. 2009;5:e1000427.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Landmesser U, Cai H, Dikalov S, et al. Role of p47 (phox) in vascular oxidative stress and hypertension caused by angiotensin. Hypertension. 2002;40:511–5.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Chobanian AV, Alexander RW. Exacerbation of atherosclerosis by hypertension. Potential mechanism and clinical implications. Arch Intern Med. 1996;156:1952–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Vecchione C, Frati A, Di Pardo A, et al. Tumor necrosis factor-a mediates hemolysis-induced vasoconstriction and the cerebral vasospasm evoked by subarachnoid hemorrhage. Hypertension. 2009;54:150–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Irani K. Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res. 2000;87:179–83.CrossRefPubMedGoogle Scholar
  28. 28.
    Cosentino F, Sill JC, Katusić ZS. Role of superoxide anions in the mediation of endothelial dependent contractions. Hypertension. 1994;23:229–35.CrossRefPubMedGoogle Scholar
  29. 29.
    Resta TC, Broughton BR, Jernigan NL. Reactive oxygen species mediate RhoA/Rho kinase–induced Ca2+ sensitization in pulmonary vascular smooth muscle following chronic hypoxia. Am J Physiol Lung Cell Mol Physiol. 2008;295:L515–29.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Grilli M, Chiu JJ, Lenardo MJ. NF-kappa B and Rel: participants in a multiform transcriptional regulatory system. Int Rev Cytol. 1993;143:1–62.CrossRefPubMedGoogle Scholar
  31. 31.
    Collins T. Endothelial nuclear factor-κB and the initiation of the atherosclerotic lesion. Lab Invest. 1993;68:499–508.PubMedGoogle Scholar
  32. 32.
    Dumortier J, Streblow DN, Moses AV, et al. Human cytomegalovirus secretome contains factors that induce angiogenesis and wound healing. J Virol. 2008;82(13):6524–35.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Juilfs DM, Soderling S, Burns F, et al. Cyclic GMP as substrate and regulator of cyclic nucleotide phosphodiesterases (PDEs). Rev Physiol Biochem Pharmacol. 1999;135:67–104.Google Scholar
  34. 34.
    Vila E, Salaices M. Cytokines and vascular reactivity in resistance arteries. Am J Physiol Heart Circ Physiol. 2005;288:H1016–21.CrossRefPubMedGoogle Scholar
  35. 35.
    Sachetelli S, Liu Q, Zhang SL, et al. RAS blockade decreases blood pressure and proteinuria in transgenic mice overexpressing rat angiotensinogen gene in the kidney. Kidney Int. 2006;69:1016–23.CrossRefPubMedGoogle Scholar
  36. 36.
    Berry C, Hamilton CA, Brosnan MJ, et al. Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internalmammary arteries. Circulation. 2000;101:2206–12.CrossRefPubMedGoogle Scholar
  37. 37.
    Rodríguez-Iturbe B, Quiroz Y, Nava M, et al. Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol. 2002;282:F191–201.CrossRefPubMedGoogle Scholar
  38. 38.
    Wang X, Falkner B, Zhu H, et al. A genome-wide methylation study on essential hypertension in young african american males. PLoS One. 2013;8(1):e53938.CrossRefGoogle Scholar
  39. 39.
    Friso S, Pizzolo F, Choi SW, et al. Epigenetic control of 11 beta–hydroxysteroid dehydrogenase 2 gene promoter is related to human hypertension. Atherosclerosis. 2008;199(2):323–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Wang Z, Lu S, Liu C, et al. Expressional and epigenetic alterations of placental matrix metalloproteinase 9 in preeclampsia. Gynecol Endocrinol. 2010;26(2):96–102.CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2016

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

Authors and Affiliations

  • Jing Hui
    • 1
  • Yuan-yuan Qu
    • 1
    • 2
  • Na Tang
    • 1
  • Yong-min Liu
    • 1
  • Hua Zhong
    • 1
  • La-mei Wang
    • 3
  • Qian Feng
    • 1
  • Zhen Li
    • 1
  • Fang He
    • 1
    Email author
  1. 1.Department of Pathophysiology/Key Laboratory of Education Ministry of Xinjiang Endemic and Ethnic DiseasesMedical College of Shihezi UniversityShiheziChina
  2. 2.Department of Emergency and Critical Care MedicineThe First Affiliated Hospital of Medical College of Shihezi UniversityShiheziChina
  3. 3.Centre of Medical Functional ExperimentsMedical College of Shihezi UniversityShiheziChina

Personalised recommendations